Author:
Weiss Armin,Frisch Christoph,Hornung Rouven,Baubin Michael,Lederer Wolfgang
Abstract
AbstractSynergistic effects of fibrinolytic and additional antithrombotic treatment during cardiopulmonary resuscitation in out-of-hospital cardiac arrest of assumed cardiac origin were evaluated retrospectively. Data were drawn from electronic files of the physician-staffed Emergency Medical Services Tyrol. During a 22-month observation period 53 adult patients were treated with tenecteplase (mean 7641 IU), 19 (32.1%) of whom received additional antithrombotic treatment with heparin (4000–5000 IU) and acetylsalicylic acid (250–500 mg). Lasting return of spontaneous circulation occurred in four of 34 patients who received fibrinolytic treatment only and in seven of 19 patients with additional antithrombotic treatment (p = 0.037). Four of five patients who were discharged from hospital had received additional antithrombotic treatment during CPR and were in appropriate neurological status (CPC 1). Considering the small sample size in this retrospective study, the argument may be still be made that fibrinolytic and adjunctive antithrombotic treatment during cardiopulmonary resuscitation in out-of-hospital cardiac arrest of assumed cardiac origin may increase the chances for survival.
Publisher
Springer Science and Business Media LLC
Reference22 articles.
1. Lott, C. et al. European Resuscitation Council Guidelines 2021: Cardiac arrest in special circumstances. Resuscitation 161, 152–218. https://doi.org/10.1016/j.resuscitation.2021.02.011 (2021).
2. Javaudin, F., Lascarrou, J. B , Le Bastard, Q., Bourry, Q., Latour, C., De Carvalho, H., Le Conte, P., Escutnaire, J., Hubert, H., Montassier, E. & Leclère, B. Research Group of the French national out-of-hospital cardiac arrest registry (GR-RéAC) thrombolysis during resuscitation for out-of-hospital cardiac arrest caused by pulmonary embolism increases 30-day survival: findings from the french national cardiac arrest registry. Chest. 156, 1167-1175, doi: https://doi.org/10.1016/j.chest.2019.07.015 (2019).
3. Tenaglia, A. N. et al. Thrombolytic therapy in patients requiring cardiopulmonary resuscitation. Am J Cardiol. 68, 1015–1019. https://doi.org/10.1016/0002-9149(91)90488-7 (1991).
4. Barthel, W. & Haustein, K. O. Cost–benefit analysis a prerequisite of a rational pharmacotherapy in cardiovascular diseases. Timely thrombolysis in the acute myocardial infarction. Int J Clin Pharmacol Ther. 34, 277–281 (1996).
5. Lederer, W., Lichtenberger, C., Pechlaner, C., Kroesen, G. & Baubin, M. Recombinant tissue plasminogen activator during cardiopulmonary resuscitation in 108 patients with out-of-hospital cardiac arrest. Resuscitation 50, 71–76. https://doi.org/10.1016/s0300-9572(01)00317-3 (2001).
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献